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The so-called dysplastic nevus first entered medical parlance 
in 1980 [1], originally known as the B-K mole in 1978, only to 
evolve over the next 34 years into a variety of names including 
familiar and atypical sporadic mole, melanocytic nevus with 
persistent lentiginous melanocytic hyperplasia, junctional or 
compound nevus with architectural atypia/disorder with or 
without cytological atypia, and Clark’s nevus, to mention but 
a few [2-6]. It is common knowledge that there is significant 
discordance and diagnostic uncertainty among consultants 
in the histopathologic diagnosis of difficult melanocytic neo-
plasia, i.e., benign or malignant [7]. The fact is there is dis-
agreement among the experts [8,9] as to what constitutes the 
so-called dysplastic nevus clinically and histopathologically 
[10]. This is so because there is inadequate and conflicting 
clinical and histopathologic criteria for a so-called dysplastic 
nevus. Both a melanoma and a dysplastic nevus have the 
same clinical features of the notorious ABCD’s (asymmetry, 
border irregularity, color variability, diameter greater than 6 
mm) What was and still is most disturbing and concerning, is 
the fact that there were reports, studies, theories and beliefs 
suggesting that the so-called dysplastic nevus is pre-malignant 
or a precursor of melanoma. Furthermore, it is said that the 
so-called dysplastic nevus may evolve into a malignant mela-
noma in either the patient or in family members, or both. 
Overlapping criteria in melanocytic neoplasia are features 
that are seen in both benign melanocytic nevi and superficial 
melanoma, such as seen in some nevi on occasion shortly 
after birth, persistent (recurrent) nevi, or traumatized nevi. In 
addition, overlapping criteria may be seen in nevi on special 
sites such as the palm/sole, genitalia (especially vulva of young 
women), umbilicus, perianal, scalp, and intertriginous folds. 
“Although the diagnosis of cutaneous malignant melanoma 
is usually based on histopathologic criteria may at times be 
inadequate in differentiating melanoma from certain types 
of benign nevi.” [11] Collectively, overlapping melanocytic 
criteria may well be the answer for such confusion between 
a so-called dysplastic nevus, melanocytic nevus and a super-
ficial melanoma [12].
Unfortunately, when a physician labels a nevus as so-
called dysplastic, or used as a hedge when unsure whether the 
lesion is benign or malignant, and therefore, “premalignant,” 
there are consequences as this diagnosis evokes considerable 
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apprehension, concern and anxiety in patients and their 
families. Furthermore, reports mushroomed forth suggest-
ing genetic transmission [13], but nowhere is there objective 
evidence that links the so-called dysplastic nevus or the so-
called dysplastic nevus syndrome to malignant melanoma 
genetically or familial [14]. What is most distressing about the 
assumption that such dysplasia presages frank malignancy is 
that the assumption lacks sufficient objective validation, and 
is likely erroneous. The fact is that in melanocytic neoplasia, 
there are a variety of melanocytic nevi [15] and a variety of 
melanomas, e.g., melanoma in situ, superficial melanoma, and 
melanoma, but there is no dysplastic nevus.
Likely causes for the formation of false mythical conclu-
sions operative in this untoward and ill-fated issue are the 
following [16]:
1)  Simple “logic,” that is, a conclusion based upon something 
that seems reasonable, e.g., heavy objects will fall faster 
then lighter ones.
2)  Notions provided by (respected?) teachers and, therefore, 
assumed to be “valid,” but later shown to be mythical.
3)  A false belief arises when a condition is named in such a way 
that implies future progression, e.g., “pre-cancerous” lesion.
Treatments for this so-called dysplastic nevus and so-
called dysplastic nevus syndrome regrettably have had the 
support and are promoted by many in the medical commu-
nity, and sorry to say, in the legal community as well. What’s 
more, there is disagreement among experts regarding screen-
ing guidelines for high-risk characteristics of cutaneous mela-
noma [17]. Among others, management includes repeated 
total body skin exams, repeated total body photographs, and 
aggressive avoidance of sun exposure. These procedures often 
lead especially and above all to the re-excision with margins 
of the so-called dysplastic nevus. Along these lines, excision 
of additional so-called dysplastic nevi (Figure 1) must also 
Figure 1. Scar on the right deltoid of a 40-year-old woman with numer-
ous scattered melanocytic nevi on the trunk and extremities, following 
a 5 mm margin re-excision of a so-called Spark’s nevus (features of a 
dysplastic and Spitz nevus). (Copyright: ©2015 Hurwitz et al.)
be considered meaningless. Sentinel lymph node biopsy is 
often considered in so-called dysplastic nevi with severe 
architectural disorder and/or cytologic atypia. This procedure 
is indeed unbelievable, extremely alarming, if not outright 
shocking. They result in traumatic psychological e.g., worry 
anxiety and fear, as well as physical e.g., unsightly cutaneous 
scars. The consequences for these far-reaching therapeutics 
and prognostications for the so-called dysplastic nevus are 
barely credible, if not potentially tragic. (Figure 2) [18,19]. 
Rarely, regrettably and inappropriately to some, additional 
procedures are thought to avoid future litigation, and/or are 
thought to be good for business.
These surgical maneuvers are reminiscent of other myths 
originating years ago, such as the mythical theory promoted 
dogmatically by Halsted—respected for his status—at Johns 
Hopkins Hospital. He postulated that attacking even small 
cancers with aggressive local surgery was the best way to 
achieve a cure, e.g., radical surgery for breast cancer, which 
included breast tissue, bone, muscle and lymph nodes, in the 
late 1890’s and early 1900’s [20]. Similar radical surgery was 
performed in New York with wide and deep surgery including 
amputation for melanoma [21]. Yet surprisingly, only about 
50% of Halsted’s mutilated radical mastectomy patients 
survived over three years, which was not superior to simpler 
procedures such as lumpectomy, introduced later.
Credible academic dermatologists and dermatopatholo-
gists have disagreed with the theories surrounding the so-
called dysplastic nevus [22-25], that they inevitably evolve 
into malignancy, another example of mythical thinking. 
Medical history is replete with examples of destroyed myths. 
For instance, it was believed for decades that peptic ulcer 
disease was simply a result of stress and anxiety, but now we 
Figure 2. Source of cartoon unknown; text modified by author.
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understand from Barry Marshall and Robin Warren that the 
problem is the result of the bacterium Helicobacter pylori 
[26], and from Harald zur Hausen that cervical squamous 
cell carcinoma is not due to sexual promiscuity, but in point 
of fact to the human papillomavirus, HPV16/18 [26]. Myths 
regarding the over diagnosis of breast cancer are yet another 
[27,28]. Furthermore, the myths of blood letting, cataract 
formation with UV light, extraterrestrial aliens, goblins, Big-
foot, and remedies of questionable repute (snake oil) exist are 
often impossible to prove or disprove, because if truth be told, 
they do not exist, akin to the mythical dysplastic nevus [29].
In summary, branding the so-called dysplastic nevus as 
tantamount to a malignancy is clearly another, unaccept-
able devastating myth. As a result, we are creating needless 
fear and anxiety to patients and physicians alike, as well as 
placing patient lives in jeopardy. If we are to maintain any 
sort of ethics in the medical profession, then this myth of the 
so-called dysplastic nevus must be stopped. It is imperative 
that the discussion herein be a stimulus for sincere and genu-
ine re-thinking and dialogue, of what has been a disastrous 
policy, and should not be flippantly dismissed as rhetoric 
or hyperbole without due consideration [30]. The late A. 
Bernard Ackerman, MD, for thirty years, strongly believed 
in this point of view, and so consequently lectured, published 
scores of videos and articles repeatedly stating that the idea 
surrounding a so-called dysplastic nevus is in fact a myth. To 
him, and too many informed, knowledgeable and well-versed 
colleagues, the so-called dysplastic nevus clearly is mistaken 
for a one of a variety of different types of melanocytic nevi, or 
a misdiagnosis of what is in reality a superficial melanoma. In 
the sincere and respectful words of the late A. Bernard Acker-
man, MD, “The so-called dysplastic nevus has had thirty-one 
synonyms over the past thirty years, and thus this term should 
be relegated to the scrap heap.” [31]
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